Claims for Patent: 10,117,848

Summary for Patent: 10,117,848

Title:	Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
Abstract:	The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
Inventor(s):	Martin P. Maguire
Assignee:	Milestone Pharmaceuticals Inc
Application Number:	US15/566,122
Patent Claims:	1. An aqueous composition formulated for nasal administration comprising a pharmaceutically acceptable salt or free base of compound I: or a racemate or enantiomer thereof, wherein compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of between 150 mg/mL and 600 mg/mL. 2. The aqueous composition of claim 1, wherein the aqueous composition comprises the S-enantiomer of compound I. 3. The aqueous composition of claim 1, wherein the concentration is 350 mg/mL±25 mg/mL. 4. The aqueous composition of claim 1, wherein the aqueous composition comprises from 40% to 85% (w/v) water. 5. The aqueous composition of claim 1, wherein the aqueous composition has a pH of 4.5±1.5. 6. The aqueous composition of claim 1, wherein the aqueous composition comprises compound I, or the racemate or enantiomer thereof, and between 0.5 and 1.5 molar equivalents of acetic acid relative to the compound. 7. The aqueous composition of claim 1, wherein the aqueous composition comprises compound I, or the racemate or enantiomer thereof, and between 0.5 and 1.5 molar equivalents of methanesulfonic acid relative to the compound. 8. The aqueous composition of claim 1, wherein the aqueous composition further comprises a chelating agent. 9. The aqueous composition of claim 1, wherein the aqueous composition further comprises EDTA. 10. The aqueous composition of claim 1, wherein the aqueous composition further comprises a pharmaceutically acceptable excipient. 11. The aqueous composition of claim 1, wherein the aqueous composition is a homogeneous composition at room temperature. 12. A nasal delivery system comprising an aqueous composition of claim 1 in a unit dosage form comprising no more than four single pump spray dosages. 13. A nasal delivery system comprising an aqueous composition of claim 1 in a unit dosage form comprising no more than two single pump spray dosages. 14. The nasal delivery system of claim 13, wherein the unit dosage form is configured for administration of no more than 200 microliters of the composition to each nostril of a patient. 15. A method of treating a disease selected from the group consisting of cardiac arrhythmia, stable angina, and migraine, said method comprising nasally administering to a patient in need thereof an aqueous composition comprising a pharmaceutically acceptable salt of compound I: or a racemate or enantiomer thereof, wherein compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of between 150 mg/mL and 600 mg/mL. 16. The method of claim 15, wherein said cardiac arrhythmia is PSVT, atrial fibrillation, or ventricular tachycardia. 17. The method of claim 15, the method comprising administering between 150 microliters and 200 microliters of the aqueous composition to the patient. 18. A method of making a solution formulated for nasal administration to a patient, the method comprising the steps of a) adding a solution comprising a first dissolved acid to the free base of a compound of claim 1 to form a mixture; b) adding to the mixture a solution comprising ethylenediaminetetracetic acid; c) heating and mechanically stirring the resulting mixture until the compound has fully dispersed within the mixture; d) adjusting the pH of the mixture to be between 3.5 and 5.5 by adding a solution comprising a second dissolved acid to the mixture; and e) diluting the mixture such that the final concentration of the compound in solution is at least 300 mg per 1 milliliter. 19. The method of claim 18, wherein the first dissolved acid is selected from the group consisting of acetic acid and methanesulfonic acid. 20. The method of claim 18, wherein the second dissolved acid is selected from the group consisting of acetic acid, sulfuric acid, and methanesulfonic acid. 21. The aqueous composition of claim 1, wherein the pharmaceutically acceptable salt is the acetate salt of the S-enantiomer of compound I. 22. An aqueous composition formulated for nasal administration comprising the acetate salt of the S-enantiomer of compound I: dissolved in the aqueous composition at a concentration of 350 mg/mL±25 mg/mL. 23. The aqueous composition of claim 22, wherein the S-enantiomer of compound I is dissolved in the aqueous composition at a concentration of 350 mg/mL. 24. The aqueous composition of claim 22, wherein the aqueous composition has a pH of 4.5±0.1. 25. The aqueous composition of claim 22, wherein the aqueous composition further comprises between 0.5 and 1.5 molar equivalents of acetic acid relative to the compound. 26. The aqueous composition of claim 22, wherein the aqueous composition further comprises sulfuric acid. 27. The aqueous composition of claim 22, wherein the aqueous composition further comprises EDTA. 28. The nasal delivery system of claim 13, wherein the aqueous composition comprises the S-enantiomer of compound I. 29. The nasal delivery system of claim 13, wherein each of the two single pump spray doses comprises 35 mg of the S-enantiomer of compound I. 30. The nasal delivery system of claim 13, wherein each of the two single pump spray doses comprises 100 microliters of the aqueous composition. 31. The method of claim 16, wherein said cardiac arrhythmia is PSVT. 32. A method of treating PSVT, said method comprising nasally administering to a patient in need thereof an aqueous composition comprising the acetate salt of the S-enantiomer of compound I: wherein the compound is dissolved in the aqueous composition at a concentration of 350 mg/mL±25 mg/mL. 33. The method of claim 32, wherein 70 mg of the acetate salt of the S-enantiomer of compound I is administered to the patient. 34. The method of claim 32, wherein the S-enantiomer of compound I is dissolved in the aqueous composition at a concentration of 350 mg/mL. 35. The method of claim 18, wherein the final concentration of the compound in solution is 350 mg/mL±25 mg/mL. 36. The method of claim 18, wherein the first dissolved acid is acetic acid and the second dissolved acid is sulfuric acid. 37. The method of claim 18, wherein, in step d), the pH is adjusted to be 4.5±0.1. 38. A method of making a solution formulated for nasal administration to a patient, the method comprising the steps of a) adding a solution comprising acidic acid to the free base of the S-enantiomer of compound I: to form a mixture; b) adding to the mixture a solution comprising ethylenediaminetetracetic acid; c) heating and mechanically stirring the resulting mixture until the S-enantiomer of compound I has fully dispersed within the mixture; d) adjusting the pH of the mixture to be 4.5±0.1 by adding a solution comprising sulfuric acid to the mixture; and e) diluting the mixture such that the final concentration of the S-enantiomer of compound I in solution is 350 mg/mL±25 mg/mL. 39. The method of claim 38, wherein the final concentration of the S-enantiomer of compound I in solution is 350 mg/mL.